Eli Lilly and Company (NYSE:LLY) – Research analysts at SunTrust Banks reduced their FY2022 earnings per share estimates for Eli Lilly and in a report released on Tuesday, May 15th. SunTrust Banks analyst J. Boris now expects that the company will post earnings of $7.77 per share for the year, down from their previous forecast of $7.78.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.21. Eli Lilly and had a net margin of 4.82% and a return on equity of 35.37%. The business had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. During the same quarter in the previous year, the business earned $0.98 earnings per share. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis.
Shares of NYSE LLY opened at $81.66 on Friday. Eli Lilly and has a 1-year low of $81.19 and a 1-year high of $81.89. The stock has a market cap of $88.12 billion, a PE ratio of 19.08, a P/E/G ratio of 1.40 and a beta of 0.26. The company has a current ratio of 1.41, a quick ratio of 1.01 and a debt-to-equity ratio of 0.64.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Wednesday, May 16th. Eli Lilly and’s payout ratio is presently 52.57%.
In other news, major shareholder Lilly Endowment Inc sold 140,000 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $81.97, for a total transaction of $11,475,800.00. Following the completion of the sale, the insider now directly owns 122,755,804 shares of the company’s stock, valued at $10,062,293,253.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Donald A. Zakrowski sold 876 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $77.55, for a total transaction of $67,933.80. Following the completion of the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at $320,281.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 361,472 shares of company stock valued at $29,328,215. 0.11% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its position in Eli Lilly and by 3.0% in the 1st quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock worth $5,089,436,000 after purchasing an additional 1,926,334 shares in the last quarter. Franklin Resources Inc. grew its position in Eli Lilly and by 14.1% in the 1st quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock worth $2,517,762,000 after purchasing an additional 4,022,251 shares in the last quarter. Geode Capital Management LLC grew its position in Eli Lilly and by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock worth $830,522,000 after purchasing an additional 406,812 shares in the last quarter. UBS Asset Management Americas Inc. grew its position in Eli Lilly and by 1.8% in the 4th quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock worth $560,509,000 after purchasing an additional 115,499 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in Eli Lilly and by 103.8% in the 1st quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock worth $362,806,000 after purchasing an additional 2,388,548 shares in the last quarter. 78.32% of the stock is owned by institutional investors and hedge funds.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.